180.30MMarket Cap-12.88P/E (TTM)
1.070High1.000Low1.19MVolume1.040Open1.050Pre Close1.22MTurnover8.46%Turnover RatioLossP/E (Static)175.05MShares21.09052wk High-13.92P/B14.50MFloat Cap0.25652wk Low--Dividend TTM14.08MShs Float21.090Historical High--Div YieldTTM6.67%Amplitude0.256Historical Low1.026Avg Price1Lot Size
Tevogen Bio Holdings Stock Forum
Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference
Monday, 23rd December at 9:38 am
WARREN, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today ...
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
7. I DO NOT give buy or sell advice
8. COH (cash on hand); AH (after hours): RTH (regular trading hours)
$Aadi Biosciences (AADI.US)$ PR AH 12/...
Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda
Thursday, 19th December at 8:30 am
WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, gen...
huh
No comment yet